Pfizer’s recent announcement that it is advancing a once-daily weight loss pill into mid-stage clinical trials later this year marks a significant development in obesity treatment, one poised to disrupt the rapidly expanding market dominated by injectable drugs.¹

Eli Lilly and Novo Nordisk, with their popular injectables Mounjaro and Wegovy, respectively, have established a dominant position in the weight loss market. However, Pfizer’s introduction of an oral alternative represents a potentially transformative shift in market dynamics, offering a convenient alternative to injectables.

Post-pandemic, Pfizer faces the challenge of diversifying its portfolio and is under pressure to innovate and capture market share in other high-potential areas. The booming weight loss drug market presents a lucrative growth avenue.

Join us for a look at Pfizer’s strategic approach to developing the once-daily pill, its competitive advantages, the implications for Pfizer’s financial performance and its positioning within the broader competitive landscape.

The Rise of Weight-Loss Drugs

Originally developed to manage Type 2 diabetes, GLP-1 agonists like Novo Nordisk’s Ozempic and Wegovy, and Eli Lilly’s Mounjaro, have demonstrated significant efficacy in weight reduction.² These injectable drugs have redefined the weight loss market, which has seen a CAGR of 47.8% in the last year, driven by their popularity.³

Currently, the market is dominated by these injectable therapies, with Novo Nordisk and Eli Lilly at the forefront. These drugs have not only shown effectiveness in clinical trials but have gained widespread acceptance among healthcare providers and patients. This class of drugs has helped patients achieve and maintain substantial weight loss, fueling their market leadership.

The market potential for weight loss treatments is immense. Analysts project that the global weight loss drug market could surpass $150 billion in annual sales by the early 2030s. This growth is fueled by rising obesity rates, increasing health awareness, and the proven effectiveness of these medications. The entry of a convenient, once-daily oral weight loss pill from Pfizer could further expand the market by attracting a broader patient base, particularly those averse to injections.⁴

Pfizer’s Strategic Move into Weight Loss

Pfizer’s recent announcement that its once-daily weight loss pill is entering clinical trials marks a strategic pivot for the pharmaceutical giant.

The reformulated once-daily pill aims to enhance patient compliance, positioning this therapy as a more convenient alternative to the existing injectable options. Pfizer’s pivot to a once-daily pill follows the company’s earlier discontinuation of a clinical trial for a twice-daily version due to unpleasant side effects.⁵

Pfizer’s once-daily pill could significantly disrupt the current market, dominated as it is by injectable GLP-1 drugs from Eli Lilly and Novo Nordisk. If Pfizer’s pill proves effective with fewer side effects, it could capture a substantial market share away from the incumbents, with the company projecting their pill may end up controlling a third of the obesity drug market.⁶

By offering a more convenient, non-invasive option, Pfizer stands to attract a broader patient base, particularly those reluctant to use injectables or who are anxious about needles. Dr. Shauna Levy, an obesity medicine specialist, pointed out that an effective oral medication could improve both accessibility and choice of treatment options.⁷

When Pfizer begins clinical trials for its weight loss pill, danuglipron, in the latter half of this year it will evaluate multiple doses to determine the optimal balance between efficacy and tolerability.

Preliminary findings are promising, suggesting that the once-daily formulation avoids the liver enzyme elevations observed with its twice-daily predecessor, lotiglipron. Early studies in over 1,400 healthy adults indicate a favourable safety profile, with no significant liver issues reported.⁸ With successful clinical trial results, Pfizer’s pill could be on the market by 2028.9

Financial and Business Implications

If clinical trials confirm the efficacy and safety of Pfizer’s once-daily weight loss pill, the potential financial impact could be substantial.

With a total potential market of $150 billion annually within the next decade, revenue projections for Pfizer’s new drug could reach several billion dollars annually, depending on market penetration and pricing strategies. Achieving even a modest market share could substantially bolster Pfizer’s revenue streams, particularly as the company seeks to diversify beyond its COVID-19 products.

Investor sentiment around Pfizer has seen a boost since the announcement of a promising new weight loss pill, with shares rising 2.8% following the news. The successful development and commercialization of danuglipron could bolster investor confidence and drive long-term growth, positioning Pfizer as a formidable competitor in the burgeoning weight loss market.10

Pfizer’s introduction of a once-daily weight loss pill has the potential to significantly disrupt an industry currently dominated by injectable drugs from Eli Lilly and Novo Nordisk. For patients and the healthcare industry, this innovation represents a shift towards more accessible and user-friendly treatment options.

LIFE ETF: Investing in Global Healthcare

Investing in ETFs can be one way to add cutting-edge healthcare to your portfolio.

Evolve Global Healthcare Enhanced Yield Fund (LIFE ETF) provides investors with exposure to twenty global blue-chip companies in the healthcare industry, with a covered call strategy that is actively managed to provide increased yield potential while helping mitigate risk. For more information about the Evolve Global Healthcare Enhanced Yield Fund or any of Evolve ETF’s lineup of exchange-traded funds, please visit our website or contact us.

 

Sources

  1. Garde, D., “Pfizer Advances Weight-Loss Pill in Race to Lucrative Market,” Bloomberg, July 11, 2024; https://www.bloomberg.com/news/articles/2024-07-11/pfizer-advances-weight-loss-pill-in-race-to-lucrative-market
  2. Castro, M.R., M.D., “GLP-1 agonists: Diabetes drugs and weight loss,” Mayo Clinic, n.d.; https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/expert-answers/byetta/faq-20057955
  3. “Weight Loss Drugs Market Trends Analysis 2018-2023 and Opportunities Forecast 2024-2033 Featuring Pfizer, Roche, Merck & Co, AbbVie, and Novartis,” Yahoo Finance, April 24, 2024; https://finance.yahoo.com/news/weight-loss-drugs-market-trends-081200226.html
  4. Erman, M. & Mishra, M., “Pfizer moves forward with once-daily weight-loss pill,” Reuters, July 11, 2024; https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-moves-forward-with-once-daily-weight-loss-drug-2024-07-11/
  5. Ibid
  6. Garde, D., “Pfizer Advances Weight-Loss Pill in Race to Lucrative Market,” Bloomberg, July 11, 2024; https://www.bloomberg.com/news/articles/2024-07-11/pfizer-advances-weight-loss-pill-in-race-to-lucrative-market
  7. Lovelace Jr., B., “Effective pills for weight loss, including an oral version of Ozempic, are on the horizon,” NBC News, June 25, 2023; https://www.nbcnews.com/health/health-news/effective-pills-weight-loss-oral-version-ozempic-are-horizon-rcna90981
  8. Erman, M. & Mishra, M., “Pfizer moves forward with once-daily weight-loss pill,” Reuters, July 11, 2024; https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-moves-forward-with-once-daily-weight-loss-drug-2024-07-11/
  9. Garde, D., “Pfizer Advances Weight-Loss Pill in Race to Lucrative Market,” Bloomberg, July 11, 2024; https://www.bloomberg.com/news/articles/2024-07-11/pfizer-advances-weight-loss-pill-in-race-to-lucrative-market
  10. Erman, M. & Mishra, M., “Pfizer moves forward with once-daily weight-loss pill,” Reuters, July 11, 2024; https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-moves-forward-with-once-daily-weight-loss-drug-2024-07-11/

Header image source: Getty Images Credit: Jamie Grill

The contents of this blog are not to be used or construed as investment advice or as an endorsement or recommendation of any entity or security discussed. These contents are not an offer or solicitation of an offer or a recommendation to buy or sell any securities or financial instrument, nor shall it be deemed to provide investment, tax or accounting advice. The information contained herein is intended for informational purposes only.
Commissions, management fees and expenses all may be associated with exchange traded funds (ETFs) and mutual funds (funds). Please read the prospectus before investing. ETFs and mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated. There are risks involved with investing in ETFs and mutual funds. Please read the prospectus for a complete description of risks relevant to ETFs and mutual funds. Investors may incur customary brokerage commissions in buying or selling ETF and mutual fund units. Certain statements contained in this blog may constitute forward-looking information within the meaning of Canadian securities laws. Forward-looking information may relate to a future outlook and anticipated distributions, events or results and may include statements regarding future financial performance. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “anticipate”, “believe”, “intend” or other similar expressions concerning matters that are not historical facts. Actual results may vary from such forward-looking information. Evolve Funds undertakes no obligation to update publicly or otherwise revise any forward-looking statement whether as a result of new information, future events or other such factors which affect this information, except as required by law.

Tags covid  drugs  eli lilly  glp-1  healthcare  LIFE ETF  obesity  pfizer